Improved Prognostic Testing for Patients with Triple Negative Breast Cancer

Approximately 40% of patients with stage I-III triple-negative breast cancer (TNBC) have recurrences after standard treatment, whereas the remaining 60% experience long-term disease-free survival. However, there are currently no clinical tests to assess the risk of recurrence in TNBC patients. Continue reading → Improved Prognostic Testing for Patients with Triple Negative Breast Cancer

Research Statement

Genomic technology has revolutionized our ability to study the molecular defects that occur in cancer. We use next-generation sequencing assays and computational analysis to study the gene expression, transcription factor binding and DNA methylation patterns in breast cancer. Our goals are to answer fundamental questions about how epigenetic gene regulation is disrupted in cancer cells as well as to discover pathways and biomarkers that may have a more immediate impact on breast cancer treatment. Our projects involve the development of new molecular methods and bioinformatics approaches to explore the cancer genome and translate our discoveries into clinical tools that improve patient care.

Varley Lab